Anacetrapib

Quote






They share the analysts opinion, nothing less and nothing more. Perhaps they feel a greater need for this to launch and launch promptly since for those that can last another 4 years, their welfare may be at stake.
 






Anonymous said:
They share the analysts opinion, nothing less and nothing more. Perhaps they feel a greater need for this to launch and launch promptly since for those that can last another 4 years, their welfare may be at stake.
Click to expand...

There will be no approval of anacetrapib until there has been PUBLISHED IN A PEER REVIEW JOURNAL a positive outcomes trial.

There is a lot of scrutiny within academia about the mechanism, especially since the torcetrapib debacle showed no significant benefit in patients who did not die...the trials were stopped. Say what you will about Radiance....the proof is not in the pudding yet.
 






Merck barely has the tenured trained people to launch a new drug like this one! Those in power now think you can launch a drug with a tracker spreadsheet, IMS and the well trained marketing team at West Point. Didn't happen with Januvia and is not happening with Dulera, when will they learn that it takes tenured folks with in depth knowledge of the customers that will move on that issue at hand? In the past competitors have bought thought leaders with program honoraria, free dinners and other enticements! That may work now someplaces but it will not fly everywhere, especially on the socialist east and west coasts! Would not want to bet on this one with our present team and knowledge! Even in the old days, we screwed up Blocadren, Primaxin, Proscar, Dolabid and Mevacor becasue marketing was stupid and we had the salesforce but bad tactics! We had better get smarter this time! We should all be shot for the marketing of Pepcid, probably one of the best drugs ever put on the market and we stayed in the shadow of Tagamet and Zantac because Merck would not spend the money! Pepcid should have been the largest $ grossing product in history, not Lipitor..Shame on us!
 






Anonymous said:
Merck barely has the tenured trained people to launch a new drug like this one! Those in power now think you can launch a drug with a tracker spreadsheet, IMS and the well trained marketing team at West Point. Didn't happen with Januvia and is not happening with Dulera, when will they learn that it takes tenured folks with in depth knowledge of the customers that will move on that issue at hand? In the past competitors have bought thought leaders with program honoraria, free dinners and other enticements! That may work now someplaces but it will not fly everywhere, especially on the socialist east and west coasts! Would not want to bet on this one with our present team and knowledge! Even in the old days, we screwed up Blocadren, Primaxin, Proscar, Dolabid and Mevacor becasue marketing was stupid and we had the salesforce but bad tactics! We had better get smarter this time! We should all be shot for the marketing of Pepcid, probably one of the best drugs ever put on the market and we stayed in the shadow of Tagamet and Zantac because Merck would not spend the money! Pepcid should have been the largest $ grossing product in history, not Lipitor..Shame on us!
Click to expand...

simply so true.
 






Top Bottom
Back
Quote